ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2025
Use of the Abbott i-STAT®1 point of care device for hCG quantification in early pregnancy.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of the Abbott i-STAT®1 point of care device for hCG quantification in early pregnancy.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesTo evaluate the use of the Abbott i-STAT®1 point-of-care-test (POCT) device for measurement of human chorionic gonadotropin (hCG) to support the management of early pregnancy complications in a remote early pregnancy unit (EPU).
methodsWomen attending the EPU who required an hCG blood test were invited to take part in the study. Participants provided an additional blood sample for whole blood hCG measurement using the Abbott i-STAT®1 analyzer. The remaining sample was sent to the hospital laboratory for hCG analysis using the Abbott Architect, the designated comparator method. Statistical analysis was performed using Analyze-IT software.
resultsA total of 61 women were recruited, including cases of pregnancy of unknown location, ectopic pregnancy, and molar pregnancy. Fourteen hCG results that were outside the i-STAT®1 assay's quantitative range, although still broadly concordant with laboratory hCG results, were excluded from statistical analysis. Analysis of the remaining 47 paired hCG results demonstrated strong agreement across the concentration range (4-2072 IU/L), with excellent Spearman correlation (r = 0.99, P < 0.001). Passing-Bablok linear regression indicated good agreement (y = 1.18 + 0.96x) and Bland-Altman analysis showed a mean difference of -23.7 IU/L (-3.5%).
conclusionsAll hCG results from the i-STAT®1 analyzer were clinically concordant with the central laboratory method, supporting its application in an EPU setting using established clinical decision thresholds. However, further verification through larger-scale studies is necessary before the i-STAT®1 analyzer can be integrated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.